StreetInsider.com News Articles

Jefferies Starts Adlai Nortye Ltd. (ANL) at Buy

Thu, 10 Sep 2026 06:10:56 -0400

Jefferies analyst Maury Raycroft initiates coverage on Adlai Nortye Ltd. (NASDAQ: ANL) with a Buy rating and a price target of $31.00.

The analyst comments "AN9025 has a pot’ly best-in-class pan-RAS profile, w/ durable tumor PD on QW dosing offering a path to a wider TI and the tolerability needed for 1L combinations. We expect 1H27 QD data to show in line-to-better efficacy/ safety vs daraxonrasib, while the still-early QW profile will be the key focus. Combined with longer-term optionality from AN4035, a CEACAM5 ADC w/ panRASi payload, ANL has multiple paths to emerge as a next-gen pan-RAS leader."

For an analyst

Jefferies Starts Adlai Nortye Ltd. (ANL) at Buy

Thu, 10 Sep 2026 06:10:56 -0400

Jefferies analyst Maury Raycroft initiates coverage on Adlai Nortye Ltd. (NASDAQ: ANL) with a Buy rating and a price target of $31.00.

For an analyst

Adlai Nortye doses first patient in AN4035 global Phase I trial

Tue, 08 Sep 2026 07:01:10 -0400

Adlai Nortye Group Ltd. (NASDAQ: ANL) announced that the first patient has been dosed with AN4035 in Australia, marking the start of a global Phase I trial evaluating the antibody-drug conjugate (ADC) in patients with CEACAM5-enriched, RAS-addicted solid tumors.

The company also received a "Study-May-Proceed" letter from the U.S. Food and Drug Administration clearing its investigational new drug application, allowing the trial to expand into the United States. Adlai Nortye said it is also filing an IND application with China's National Medical Products Administration.

AN4035 is described by the company as a first-in-class ADC that targets the CEACAM5 protein and delivers a

Adlai Nortye doses first patient in AN4035 global Phase I trial

Tue, 08 Sep 2026 07:01:10 -0400

AN4035 is described by the company as a first-in-class ADC that targets the CEACAM5 protein and delivers a

Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC

Tue, 08 Sep 2026 07:00:00 -0400

First-in-class CEACAM5-targeting ADC armed with a pan-RAS(ON) inhibitor – designed for tumor-selective RAS pathway inhibition

First patient dosed in Australia; global Phase I initiated

U.S. FDA cleared IND with "Study-May-Proceed" letter

SINGAPORE and NORTH BRUNSWICK, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that the first patient has been dosed with AN4035 in Australia, initiating the global Phase I trial in patients with CEACAM5-enriched RAS-addicted solid tumors. The

Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC

Tue, 08 Sep 2026 07:00:00 -0400

First-in-class CEACAM5-targeting ADC armed with a pan-RAS(ON) inhibitor – designed for tumor-selective RAS pathway inhibition

First patient dosed in Australia; global Phase I initiated

U.S. FDA cleared IND with "Study-May-Proceed" letter

Lucid Capital Markets Starts Adlai Nortye Ltd. (ANL) at Buy

Tue, 08 Sep 2026 06:37:37 -0400

(Updated - September 8, 2026 6:37 AM EDT)

Lucid Capital Markets analyst Dev Prasad initiates coverage on Adlai Nortye Ltd. (NASDAQ: ANL) with a Buy rating and a price target of $49.00.

The analyst comments "We are assuming coverage of Adlai Nortye with a Buy rating and a $49 PT. Our investment thesis is primarily driven by AN9025, an oral pan-RAS(ON) inhibitor with a differentiated preclinical profile across potency, durability and therapeutic-window potential. Following daraxonrasib’s approval, AN9025 no longer needs to establish that pan-RAS biology can work clinically; instead, the opportunity is to demonstrate competitive efficacy with a differentiated therapeutic window capable

Lucid Capital Markets Starts Adlai Nortye Ltd. (ANL) at Buy

Tue, 08 Sep 2026 06:37:37 -0400

(Updated - September 8, 2026 6:37 AM EDT)

Lucid Capital Markets analyst Dev Prasad initiates coverage on Adlai Nortye Ltd. (NASDAQ: ANL) with a Buy rating and a price target of $49.00.

Form 4 Adlai Nortye Group Ltd. For: Aug 24 Filed by: Ye Xiaofeng

Wed, 26 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260826/26982204.html

Form 4 Adlai Nortye Group Ltd. For: Aug 24 Filed by: Ye Xiaofeng

Wed, 26 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260826/26982204.html

Form 6-K Adlai Nortye Ltd. For: Aug 19

Wed, 19 Aug 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260819/26947647.html

Form 6-K Adlai Nortye Ltd. For: Aug 19

Wed, 19 Aug 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260819/26947647.html

Form SCHEDULE 13G/A Adlai Nortye Ltd. Filed by: Venrock Healthcare Capital Partners III, L.P.

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932185.html

Form SCHEDULE 13G/A Adlai Nortye Ltd. Filed by: Venrock Healthcare Capital Partners III, L.P.

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932185.html

Form SCHEDULE 13G/A Adlai Nortye Ltd. Filed by: Cormorant Asset Management, LP

Fri, 14 Aug 2026 14:00:00 -0400

si-local-file:///var/storage/secattach/20260814/26928691.html

Form SCHEDULE 13G/A Adlai Nortye Ltd. Filed by: Cormorant Asset Management, LP

Fri, 14 Aug 2026 14:00:00 -0400

si-local-file:///var/storage/secattach/20260814/26928691.html

Form 6-K Adlai Nortye Ltd. For: Aug 14

Fri, 14 Aug 2026 07:23:00 -0400

si-local-file:///var/storage/secattach/20260814/26924530.html

Form 6-K Adlai Nortye Ltd. For: Aug 14

Fri, 14 Aug 2026 07:23:00 -0400

si-local-file:///var/storage/secattach/20260814/26924530.html

Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress

Fri, 14 Aug 2026 07:00:00 -0400

Enrollment ongoing in both QD and QW arms of global Phase I trial of pan-RAS(ON) inhibitor AN9025

First regulatory approval obtained for Phase I trial of pan-RAS(ON) ADC AN4035

Two leading medical oncologists appointed to Scientific Advisory Board

SINGAPORE and NORTH BRUNSWICK, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced its business highlights and its first half financial results for the

Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress

Fri, 14 Aug 2026 07:00:00 -0400

Enrollment ongoing in both QD and QW arms of global Phase I trial of pan-RAS(ON) inhibitor AN9025

First regulatory approval obtained for Phase I trial of pan-RAS(ON) ADC AN4035

Two leading medical oncologists appointed to Scientific Advisory Board

Form 3 Adlai Nortye Ltd. For: Mar 18 Filed by: Birgerson Lars Erik

Tue, 04 Aug 2026 10:58:00 -0400

si-local-file:///var/storage/secattach/20260804/26863821.html

Form 3 Adlai Nortye Ltd. For: Mar 18 Filed by: Birgerson Lars Erik

Tue, 04 Aug 2026 10:58:00 -0400

si-local-file:///var/storage/secattach/20260804/26863821.html

Form 6-K Adlai Nortye Ltd. For: Aug 03

Mon, 03 Aug 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260803/26854169.html

Form 6-K Adlai Nortye Ltd. For: Aug 03

Mon, 03 Aug 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260803/26854169.html

Adlai Nortye clears regulatory hurdle for AN4035 cancer drug trial

Mon, 03 Aug 2026 07:02:41 -0400

Adlai Nortye Ltd. (NASDAQ: ANL) announced it has submitted a Clinical Trial Notification to Australia's Therapeutic Goods Administration and received approval from the Human Research Ethics Committee to begin a phase I clinical trial of AN4035, an antibody drug conjugate targeting CEACAM5-enriched, RAS-addicted solid tumors.

AN4035 is designed to deliver a pan-RAS(ON) inhibitor payload to tumor cells by targeting the CEACAM5 antigen, which is overexpressed in colorectal, pancreatic, and lung cancers. The drug is the first candidate from the company's RASiCA™ platform.

The phase I trial will assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AN4035 as a monotherapy and in